|
|
3020 Callan Road
San Diego, CA 92121 USA
phone:(858) 458-0900
fax:858-458-0994
|
|
| Symbol |
CYTX |
| Exchange |
NASDAQ |
| Founded |
1996 |
| Employees |
93 |
|
|
| www.cytoritx.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Medical technologies for regenerative medicine. |
|
| Management |
| Christopher J. Calhoun, Chief Executive Officer; Marc H. Hedrick, M.D., President; Mark E. Saad, Chief Financial Officer; Douglas Arm, Ph.D., Vice President; Kenneth K. Kleinhenz, Vice President; Alexander M. Milstein, M.D., Vice President; Bruce Reuter, Senior Vice President; Seijiro N. Shirahama, President |
| |
|
|
|
|
|
|
|
| Keywords |
| regenerative medicine, cosmetic, reconstructive, cardiovascular, disease, wound healing |
|
|
|
| Description |
|
Cytori Therapeutics, Inc. has actualized cutting edge regenerative medicine technology
for the treatment of serious medical conditions. The company�s proprietary technology,
termed Celution System, uses a small sample of a patient�s adipose (fat) tissue to isolate
and mature the patient�s own stem cell population that is then used to treat medical
conditions. Stem cell�s obtained using Cytori�s technology are being developed for the
treatment of cardiovascular disease, spinal disc degeneration, gastrointestinal disorders,
liver and renal disease, and pelvic health conditions. |
|
| Products / Services |
The principal products of Cytori Therapeutics include the Celution System family of products. These products processes patients' cells at the bedside in real time. Each member of the Celution System family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzymes, and related instrumentation.
The company also offers Celution 800/CRS System for the European cosmetic and reconstructive surgery market through a network of medical distributors.
Further, it offers the Celution 900/MB in Japan through its commercialization partner as part of the StemSource Cell Bank, which prepares cells for cryopreservation.
|
|
| Technology / Differentiation |
| Cytori Therapeutics? goal is to provide access to clinical grade Adipose-Derived Stem and Regenerative Cells (ADRCs). ADRCs, sometimes referred to as stromal vascular fraction cells, are a heterogeneous or mixed population of cells found in adipose tissue. ADRCs are usually obtained through a simple liposuction procedure. |
|
| Market / Customers |
Green Hospital Supply is responsible for all sales and marketing while Cytori is responsible for manufacturing the Celution 900/MB System and sourcing all necessary equipment.
|
|
| Competitors / Substitutes / Alternatives |
Aastrom Biosciences, Inc., Baxter International Inc., Osiris Therapeutics, Inc.
|
|
| Status |
| As of December 31, 2008, the Company has two clinical trials underway in Europe for adipose-derived stem and regenerative cells, processed with the Celution 600 and 800 System, for the treatment of cardiovascular disease. Other areas for the applications of the Celution System family of products under investigation include gastrointestinal disorders, vascular disease, pelvic health conditions, and orthopedic and spinal applications. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
